Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EuTYPH-C
- Development stage
- Phase 3
- Lead developer
- EuBiologics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
EuTYPH-C is a next-generation typhoid conjugate vaccine developed by EuBiologics Co., LTD, in collaboration with PATH. It is designed to prevent typhoid fever by inducing both B cell and T cell immune responses. The vaccine utilizes EuBiologics' proprietary CRM197 carrier protein conjugated with Vi polysaccharide to enhance its immunogenicity and provide longer-lasting protection. Clinical trials have demonstrated its safety and immunogenicity, showing non-inferiority compared to the WHO prequalified comparator vaccine, Typbar TCV®. The vaccine has completed Phase 3 clinical trials in typhoid-endemic populations in sub-Saharan Africa and has received export approval from the Korean Ministry of Food and Drug Safety, with a WHO prequalification application currently under review.
- Brand names
- EuTYPH-C Inj.
- Other names
- Vi-CRM197 typhoid conjugate vaccineVi-CRM-197 typhoid conjugate vaccineVi-CRM 197 typhoid conjugate vaccineEuBiologics TCV
02
Targets
Vi polysaccharide-specific B-cell receptorVi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on EuTYPH-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EuTYPH-C.